glp 1 and gip mechanism of action The dual glucose-dependent insulinotropic polypeptide (GIP) glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology The Influence of Glucagon-like Peptide-1

Its long-term safety is simply not yet established, because it remains investigational

Just asked, months later, whether they felt better [14]

They also agreed the drugs are not a cure-all

Aimen Arij Jun 19, 2026 34 min Cardiovascular & Longevity How Is NAD+ Depletion Linked to the Progression of Cardiovascular Disease

Our approach ensures patients receive safe and effective treatment, helping to restore energy and improve cognitive function to support overall wellbeing

Table 2 shows that 43.1% of participants with experience using GLP-1 drugs expected the drugs to have a significant impact on preferences and purchasing habits, compared to just 14.3% of those without experience with the drugs